Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC

Phase 1/2 Completed 160 enrolled Zhejiang University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died or lost to follow-up. To analyze the difference in efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for colorectal cancer, so as to find a better postoperative adjuvant treatment model.

Timeline

Start: 2018-08-12
Primary completion: 2021-08-24
Completion: 2021-08-24

Outcome

Met primary endpoint

paper All grade thrombocytopenia occurred in 33% and 49% patients at biweekly and triweekly group, respectively (P = 0.02). PMID 40644418 ↗

Publications

Zhang H, Wang D, Tong Z, Xiang T, Zhu X, Liu L, Zheng Y, Zhao P, Fang W, Chen W. Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial. PLoS One. 2025 Jul 11;20(7):e0313472. doi: 10.1371/journal.pone.0313472. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous